PURE BIOSCIENCE by PURE Bioscience Financials - Benzinga

SPY765.34−0.78%QQQ736.42−1.09%BTC/USD83,499.99−1.12%DIA513.99−0.68%GLD378.24−3.86%TLT78.65−0.85%

PURE BIOSCIENCE by PURE Bioscience

PUREOTCQB

Trade with Public

Trade with Public

$0.0636

-0.0064-9.14%

At close: Sep 28, 5:00 PM EST

Overview News Earnings ForecastFinancialsSentiment Ownership Compare

PURE BIOSCIENCE by PURE Bioscience Financials

PURE BIOSCIENCE by PURE Bioscience (PURE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
PURE Bioscience Q3 EPS $(0.01), Same YoY, Sales $506.000K Up From $491.000K YoY

PURE Bioscience (OTC:PURE) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $506.000 thousand in sales this quarter. This is a 3.05 percent increase

Benzinga Newsdesk

PRO
PURE Bioscience Q2 EPS $(0.01), Same YoY, Sales $443.000K Up From $391.000K YoY

PURE Bioscience (OTC:PURE) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $443.000 thousand in sales this quarter. This is a 13.30 percent increase

Benzinga Newsdesk

PRO
PURE Bioscience Q1 Sales $707.000K Up From $556.000K YoY

PURE Bioscience (OTC:PURE) reported $707.000 thousand in sales this quarter. This is a 27.16 percent increase over sales of $556.000 thousand the same period last year.

Benzinga Newsdesk

PRO
PURE Bioscience Q4 Sales $764.000K Up From $474.000K YoY

PURE Bioscience (OTC:PURE) reported $764.000 thousand in sales this quarter. This is a 61.18 percent increase over sales of $474.000 thousand the same period last year.

Benzinga Newsdesk

PRO
PURE Bioscience Q3 EPS $(0.01), Same YoY, Sales $491.00K Up From $441.00K YoY

PURE Bioscience (OTC:PURE) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $491.00 thousand in sales this quarter. This is a 11.34 percent increase

Benzinga Newsdesk

PRO
PURE Bioscience Q2 2025 EPS ($0.01) In-Line YoY; Revenue $391K Up From $325K YoY.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved